Respicardia Announces Highmark Coverage for the remedē® System in Patients with Central Sleep Apnea
Expanded insurance coverage now available in Pennsylvania, Delaware and West Virginia
TREATING
CENTRAL SLEEP APNEA
remedē News
Monument Health performs remedē first System implant in the Dakotas
Respicardia, Inc. announced today that Monument Health in Rapid City, South Dakota is the first center in the Dakotas to treat patients with the remedē® System, an implantable device that uses phrenic nerve stimulation to treat central sleep apnea (CSA).
Novant Health Forsyth Medical Center treats 25th patient with remedē
Respicardia, Inc. announced today that Novant Health Forsyth Medical Center in Winston-Salem, NC has treated its 25th patient with the remedē® System, an implantable device that treats central sleep apnea (CSA) by using phrenic nerve stimulation.
Transvenous phrenic nerve stimulation (The remedē System) shows sustained safety and efficacy through 5 years
Trial results showed consistent improvement in sleep disordered breathing, arousals, sleep architecture, and daytime sleepiness through 5 years.
Richard L. Roudebush VA Medical Center performs remedē first System implant in Indiana
Respicardia, Inc. announced today that Richard L. Roudebush VA Medical Center in Indianapolis is the first center in Indiana to treat patients with the remedē® System, an implantable device that uses phrenic nerve stimulation to treat central sleep apnea (CSA).